Odyssey Therapeutics (NASDAQ:ODTX) Stock Rating Upgraded by UBS Group

Odyssey Therapeutics (NASDAQ:ODTX) was upgraded by analysts at UBS Group to a “strong-buy” rating in a report issued on Monday, Zacks reports.

Several other brokerages also recently issued reports on ODTX. Wall Street Zen downgraded shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 20th. Raymond James Financial began coverage on shares of Odyssey Therapeutics in a report on Thursday, October 8th. They issued an “outperform” rating and a $42.00 price objective on the stock. HC Wainwright started coverage on shares of Odyssey Therapeutics in a research report on Thursday, August 27th. They issued a “buy” rating and a $44.00 price objective on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Weiss Ratings began coverage on shares of Odyssey Therapeutics in a research note on Tuesday, August 11th. They set a “sell (d+)” rating for the company. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $35.33.

Odyssey Therapeutics Stock Down 5.6%

NASDAQ:ODTX opened at $17.24 on Monday. Odyssey Therapeutics has a 12-month low of $15.10 and a 12-month high of $29.05. The firm has a market cap of $828.55 million and a price-to-earnings ratio of -2.55. The firm’s 50 day moving average is $22.71.

Odyssey Therapeutics (NASDAQ:ODTX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) EPS for the quarter. As a group, sell-side analysts forecast that Odyssey Therapeutics will post -6.08 EPS for the current fiscal year.

Institutional Trading of Odyssey Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new stake in Odyssey Therapeutics during the second quarter worth approximately $4,162,000. State Street Corp acquired a new stake in Odyssey Therapeutics in the second quarter worth approximately $1,477,000. Finally, The Manufacturers Life Insurance Company bought a new position in Odyssey Therapeutics during the 2nd quarter valued at $601,000.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for serious diseases, with an emphasis on immunology and oncology. The company uses a combination of human genetics, functional genomics, computational biology, machine learning and medicinal chemistry to identify disease targets and advance potential therapeutic programs.

Odyssey’s research and development activities are centered on small-molecule medicines designed to address genetically validated targets and specific disease mechanisms.